contadores web
Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Short article

Vol. 24 No. 3 (2022)

Gastrointestinal bleeding prophylaxis in internal medicine patients of a univeristy hospital

DOI
https://doi.org/10.22267/rus.222403.282
Submitted
November 16, 2020
Published
2022-08-30

Abstract

Introduction: Anti-ulcer medications are frequently used in hospitalized patients, yet their use is not usually indicated. Objective: To describe the frequency of prescription and indication of medications to prevent gastrointestinal bleeding in hospitalized patients. Materials and methods: A cross-sectional, descriptive, prospective study was carried out in the Internal Medicine service of the Surgery Society of Bogota-San Jose Hospital of Bogota (Colombia). Excluded patients were those with either a gastrointestinal bleeding diagnosis or a history of allergy to anti-ulcer medications. Demographic data and information regarding prescribed medications were collected. It was determined whether the medicine indication was adequate and the type of prescription error was identified. Results: 179 patients were included in the study, 57% (102) of which were women. The average age was 61.3 (±20.2) years old. Infectious disease was the main admission diagnosis (76; 42.4%). A 92.17% (165) of the total number of patients received medications to prevent gastrointestinal bleeding. This indication was adequate for 75 (41.89%) patients. The most frequent error was their use in bleeding low-risk patients (101; 97.1%). Conclusion: A high percentage of patients received medication to prevent gastrointestinal bleeding. However, in about half of these patients it was not indicated.

References

  1. Marik PE, Vasu T, Hirani A, Pachinburavan M. Stress ulcer prophylaxis in the new millennium: A systematic review and meta-analysis. Crit Care Med [Internet]. 2010; 38(11):2222-8. DOI: 10.1097/ccm.0b013e3181f17adf.
  2. Marker S, Krag M, Møller MH. What’s new with stress ulcer prophylaxis in the ICU? Intensive Care Med [Internet]. 2017; 43(8):1132-4. DOI: 10.1007/s00134-017-4733-0.
  3. Mendes JJ, Silva MJ, Miguel LS, Gonçalves MA, Oliveira MJ, Oliveira C da L, et al. Sociedade Portuguesa de Cuidados Intensivos guidelines for stress ulcer prophylaxis in the intensive care unit. Rev Bras Ter Intensiva [Internet]. 2019; 31(1):5-14. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443317
  4. Wang Y, Ye Z, Ge L, Siemieniuk RAC, Wang X, Wang Y, et al. Efficacy and safety of gastrointestinal bleeding prophylaxis in critically ill patients: systematic review and network meta-analysis. BMJ [Internet]. 2020; 368:l6744. DOI: 10.1136/bmj.l6744.
  5. PEPTIC Investigators for the Australian and New Zealand Intensive Care Society Clinical Trials Group, Alberta Health Services Critical Care Strategic Clinical Network, and the Irish Critical Care Trials Group. Effect of stress ulcer prophylaxis with proton pump inhibitors vs histamine-2 receptor blockers on in-hospital mortality among ICU patients receiving invasive mechanical ventilation: The PEPTIC randomized clinical trial. JAMA [Internet]. 2020; 323(7):616-26. DOI: 10.1001/jama.2019.22190.
  6. Cook D, Guyatt G. Prophylaxis against upper gastrointestinal bleeding in hospitalized patients. N Engl J Med [Internet]. 2018; 378(26):2506-16. DOI: 10.1056/nejmra1605507.
  7. Liu Y, Li D, Wen A. Pharmacologic prophylaxis of stress ulcer in non-ICU patients: A systematic review and network meta-analysis of randomized controlled trials. Clin Ther [Internet]. 2020; 42(3):488-98.e8. DOI: 10.1016/j.clinthera.2020.01.008.
  8. ASHP Commission on Therapeutics. ASHP therapeutic guidelines on stress ulcer prophylaxis. Am J Health Syst Pharm [Internet]. 1999; 56(4):347-79. DOI: 10.1093/ajhp/56.4.347.
  9. Savarino V, Dulbecco P, de Bortoli N, Ottonello A, Savarino E. The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal. Eur J Intern Med [Internet]. 2017; 37:19-24. DOI: 10.1016/j.ejim.2016.10.007.
  10. Diaztagle JJ, Cruz RH, Eslava DF, Briceño JF, Hernández AC, Jiménez N, et al. Sangrado gastrointestinal en pacientes hospitalizados. Repert Med Cir [Internet]. 2014; 23(1):9-17. DOI: 10.31260/RepertMedCir.v23.n1.2014.736.
  11. Nehra AK, Alexander JA, Loftus CG, Nehra V. Proton pump inhibitors: Review of emerging concerns. Mayo Clin Proc [Internet]. 2018; 93(2):240-6. DOI: 10.1016/j.mayocp.2017.10.022.
  12. Masood U, Sharma A, Bhatti Z, Carroll J, Bhardwaj A, Sivalingam D, et al. A successful pharmacist-based quality initiative to reduce inappropriate stress ulcer prophylaxis use in an academic medical intensive care unit. Inquiry [Internet]. 2018; 55:0046958018759116. DOI: 10.1177/0046958018759116.
  13. Lanza FL, Chan FKL, Quigley EMM, Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol [Internet]. 2009; 104(3):728-38. DOI: 10.1038/ajg.2009.115.
  14. Corral-Gudino L, Rivas-Lamazares A, González-Fernández A, Rodríguez-María M, Aguilera-Sanz C, Tierra-Rodríguez A, et al. Does my patient really need this at admission? Seven opportunities for improving value in patient care during their hospitalization. Eur J Intern Med [Internet]. 2019; 66:92-8. DOI: 10.1016/j.ejim.2019.06.007.
  15. Horsa BA, Ayele Y, Ayalew MB. Assessment of pharmacologic prophylaxis use against stress ulcer in the medical wards of University of Gondar Hospital. SAGE Open Med [Internet]. 2019; 7:2050312119827409. DOI: 10.1177/2050312119827409.
  16. Masoompour SM, Kasaee R, Mahdaviazad H. Evaluation of adherence to American society of health-system pharmacists guidelines: Stress ulcer prophylaxis in Shiraz, Iran. Gastroenterol Nurs [Internet]. 2017; 40(6):491-5. DOI: 10.1097/sga.0000000000000278.
  17. Machado-Alba JE, Castrillón-Spitia JD, Londoño-Builes MJ, Fernández-Cardona A, Campo-Betancourth CF, Ochoa-Orozco SA, et al. An economic analysis of inadequate prescription of antiulcer medications for in-hospital patients at a third level institution in Colombia. Rev Esp Enferm Dig [Internet]. 2014; 106(2):77-85. DOI: 10.4321/s1130-01082014000200002.
  18. Valle B, Díaz JA, López JJ, Calderón CM. Evaluación de la prescripción profiláctica de omeprazol y ranitidina mediante la identificación de factores de riesgo de sangrado gastrointestinal. Rev Colomb Cienc Quim Farm [Internet]. 2017; 46(1):36-47. DOI: 10.15446/rcciquifa.v46n1.67289.
  19. Amaral MC, Favas C, Alves JD, Riso N, Riscado MV. Stress-related mucosal disease: Incidence of bleeding and the role of omeprazole in its prophylaxis. Eur J Intern Med [Internet]. 2010; 21(5):386-8. DOI: 10.1016/j.ejim.2010.06.010.
  20. Wijaya D, Padolo E, Ardianto C, Sumarno, Matulatan F, Alderman CP, et al. Analysis of the use and cost of stress ulcer prophylaxis for surgical inpatients. J Basic Clin Physiol Pharmacol [Internet]. 2020; 30(6):20190306. DOI: 10.1515/jbcpp-2019-0306.
  21. Tan B, Norman R, Litton E, Heath C, Hawkins DJ, Krishnamurthy R, et al. Incidence and cost of stress ulcer prophylaxis after discharge from the intensive care unit: a retrospective study. Crit Care Resusc [Internet]. 2016; 18(4):270-4. Disponible en: https://pubmed.ncbi.nlm.nih.gov/27903209/
  22. Tariq R, Singh S, Gupta A, Pardi DS, Khanna S. Association of gastric acid suppression with recurrent Clostridium difficile infection: A systematic review and meta-analysis. JAMA Intern Med [Internet]. 2017; 177(6):784-91. DOI: 10.1001/jamainternmed.2017.0212.

Downloads

Download data is not yet available.